(Q37458317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Qian Shi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

1 reference

24 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

102-111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19390940%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10147-009-0885-4

26 January 2020

exact match

0 references

cites work

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Surrogate end points in clinical research: hazardous to your health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

The scandal of poor medical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Surrogates, semantics, and sensible public policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Progression-free survival as a surrogate endpoint in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0885-4

Validity, credibility, and applicability: the rise and rise of the surrogate

21 January 2018

1 reference

12 December 2020

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

12 December 2020

Information theory-based surrogate marker evaluation from several randomized clinical trials with binary endpoints, using SAS

1 reference

12 December 2020

Intermediate markers as surrogate endpoints in cancer research

1 reference

12 December 2020

Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials

1 reference

12 December 2020

Alternative methods to evaluate trial level surrogacy.

1 reference

12 December 2020

A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint

1 reference

12 December 2020

Surrogate endpoints in clinical trials: cardiovascular diseases.

1 reference

12 December 2020

Role of surrogate end points in the evaluation of drugs for heart failure

1 reference

12 December 2020

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

1 reference

12 December 2020

Radiology: Where are we now with radiographic assessment of rheumatoid arthritis?

1 reference

12 December 2020

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

1 reference

12 December 2020

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

12 December 2020

Surrogate Endpoints And FDA’s Accelerated Approval Process

1 reference

12 December 2020

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

12 December 2020

Surrogate endpoints in clinical trials: ophthalmologic disorders

1 reference

12 December 2020

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

12 December 2020

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches

1 reference

12 December 2020

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.

1 reference

12 December 2020

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Evaluating surrogate endpoints

1 reference

12 December 2020

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

12 December 2020

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

1 reference

12 December 2020

Surrogate endpoints in clinical trials: cancer

1 reference

12 December 2020

Estimating the proportion of treatment effect explained by a surrogate marker

1 reference

12 December 2020

Debate: The slippery slope of surrogate outcomes

1 reference

12 December 2020

Biomarkers and surrogate markers: an FDA perspective

1 reference

12 December 2020

The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat

1 reference

12 December 2020

Surrogate marker evaluation from an information theory perspective

1 reference

12 December 2020

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

1 reference

12 December 2020

Hepatology may have problems with putative surrogate outcome measures

1 reference

12 December 2020

Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints

1 reference

12 December 2020

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

1 reference

12 December 2020

Exploring and validating surrogate endpoints in colorectal cancer

1 reference

12 December 2020

Preliminary analysis of the Concorde trial. Concorde Coordinating Committee

1 reference

12 December 2020

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

1 reference

12 December 2020

On meta-analytic assessment of surrogate outcomes.

1 reference

12 December 2020

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

12 December 2020

Perspective: validating surrogate markers--are we being naive?

1 reference

12 December 2020

Surrogate markers in AIDS and cancer trials

1 reference

12 December 2020

Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective

1 reference

12 December 2020

Estimating the proportion of treatment effect explained by a surrogate marker.

1 reference

12 December 2020

The validation of surrogate endpoints in meta-analyses of randomized experiments

1 reference

12 December 2020

Advanced methods in meta-analysis: multivariate approach and meta-regression.

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

12 December 2020

Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints

1 reference

12 December 2020

Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes

1 reference

12 December 2020

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

12 December 2020

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

1 reference

12 December 2020

Accelerated approval of oncology products: a decade of experience

1 reference

12 December 2020

Statistical evaluation of biomarkers as surrogate endpoints: a literature review

1 reference

12 December 2020

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

1 reference

12 December 2020

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

1 reference

12 December 2020

Surrogate endpoints: do they really contribute in therapeutic decision making?

1 reference

12 December 2020

Food and Drug Administration requirements for approval of new anticancer drugs

1 reference

12 December 2020

Small trials focusing on surrogate end points may be uninformative

1 reference

12 December 2020

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

12 December 2020

Two simple approaches for validating a binary surrogate endpoint using data from multiple trials

1 reference

12 December 2020

Statistical challenges in the evaluation of surrogate endpoints in randomized trials

1 reference

12 December 2020

Statistical validation of intermediate endpoints for chronic diseases

1 reference

12 December 2020

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

12 December 2020

Assessing surrogates as trial endpoints using mixed models

1 reference

12 December 2020

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials

1 reference

12 December 2020

A perfect correlate does not a surrogate make

1 reference

12 December 2020

What are surrogate outcome measures and why do they fail in clinical research?

1 reference

12 December 2020

An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker.

1 reference

12 December 2020

Surrogate markers: back to the future

1 reference

12 December 2020

Criteria for the validation of surrogate endpoints in randomized experiments.

1 reference

12 December 2020

Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer

1 reference

12 December 2020

Evaluating surrogate markers.

1 reference

12 December 2020

Surrogate Markers in Clinical Studies: Problems Solved or Created?

1 reference

12 December 2020

Educating health professionals about drug and device promotion: advocates' recommendations

1 reference

12 December 2020

A perspective on surrogate endpoints in controlled clinical trials

1 reference

12 December 2020

Surrogate endpoints: a basis for a rational approach

1 reference

12 December 2020

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

12 December 2020

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

12 December 2020